Long COVID Treatment Trial-Tirzepatide; LoCITT-T
Listed on 2026-07-08
-
Healthcare
-
Research/Development
GLMA:
Health Professionals Advancing LGBTQ Equality Long COVID Treatment Trial-Tirzepatide (LoCITT-T)
Overview: An estimated 400 million people across the world have Long COVID. So far there has been little research and few effective treatments available. The Long COVID Treatment Trial Tirzepatide (LoCITT-T), sponsored by Scripps Research, will see if a medicine called tirzepatide helps people with Long COVID feel better and could help millions of people living with Long COVID today. Participation can be completed entirely from home, no in-person visits needed.
Study Type: Mixed Methods
IRB Approved: Yes
Target Audience: Adults (18 years and older), living in the U.S. (excluding Hawaii), documentation of Long COVID diagnosis and other inclusion criteria.
How to Apply: Click the link
Study Contact: LoCITT Study Team
longcovid-t
1629 K St. NW
Suite 300
Washington, DC 20006
(If this job is in fact in your jurisdiction, then you may be using a Proxy or VPN to access this site, and to progress further, you should change your connectivity to another mobile device or PC).